Merck KGaA has partnered with German tech company AMCM to carry out clinical testing on tablets manufactured using 3D printing.
The collaboration – which could be a “massive move towards digitalization of the industry,” according to Merck’s chief strategy officer Isabel de Paoli – will focus initially on formulation development and production of 3D printed tablets for clinical trials.
Merck and AMCM – part of the metal and polymer 3D printing specialist EOS group – are working on the development of a prototype tablet printer that they hope will be ready for testing later this year.
3D printing has already reached the commercial stage in pharma, after Aprecia Pharmaceuticals claimed FDA approval for its epilepsy therapy Spritam (levetiracetam) in 2015.
Scott Drikakis, healthcare segment leader – Americas, Stratasys, explores how 3D printing could enable medical device manufacturers to overcome current limitations, improve clinical validation, and change the game of medical device testing.
The use of 3D printing in healthcare is not a new phenomenon. Those who keenly pay attention to technology developments within the sector will be unsurprised to hear of its use. In recent years, Stratasys has worked with customers across the world to improve patient care and communication, accelerate clinical validation and increase innovation. In Europe, hospitals such as CHU Bordeaux and Guy’s and St Thomas’ have utilized the very latest in advanced, multi-material 3D printing to create patient-specific 3D medical models to help plan complex procedures. Equally, customers such as Nidek Technologies have been able to dramatically accelerate clinical trials when incorporating 3D printing into the device testing process.
Despite these incredible advances, 3D printing has had its limitations in terms of organ realism and biomechanical functionality and, to date, has not offered a testing method which covers all problem areas. This means that many medical device manufacturers are still also reliant on traditional testing methods. These predominantly involve the use of human cadavers, animals or virtual modeling. However, as with the current 3D printing solutions available, each of these methods comes with their own distinct limitations. These can range from ethical concerns to lengthy and costly development processes. As a result, medical institutions are continuing to push for technological advancements to overcome such issues. To help make this a realization, it is essential to create a solution that can directly target the specific drawbacks that each of the traditional methods of testing have, as well as overcome the current limitations of 3D printing itself. The recently launched J750 Digital Anatomy 3D printer claims to address all of these issues. Through using advanced new materials and software, this printer can replicate the actual feel, responsiveness and biomechanics of human anatomy.
“3D printing will be a game-changer for the MRO industry worldwide.”
Pratt & Whitney is set to introduce a 3D printed aero-engine component into its maintenance, repair and overhaul (MRO) operations by mid-2020 after a successful collaboration with ST Engineering.
The two companies came together to leverage 3D printing technology to facilitate faster and more flexible repair solutions, with contributions also coming from Pratt & Whitney’s repair specialist Component Aerospace Singapore.
Component Aerospace Singapore provides engine part repair for combustion chambers, fuel systems and manifolds; ST Engineering boasts ‘production-level 3D capabilities’ and experience applying 3D printing in land transport systems; and Pratt & Whitney is a specialist in design and engineering.